MicroRNA-152 Suppresses Cisplatin Resistance in A549 Cells

Overview

Journal Oncol Lett

Specialty Oncology

Date 2019 Oct 16

PMID 31611969

Citations 8

Authors

Wenfei Zhao

Hongyun Li

Shanshan Yang

Di Guo

Jing Chen

Shaoyi Miao

Yi Xin

Miaomiao Liang

Affiliations

Soon will be listed here.

Abstract

The present study aimed to investigate the association between microRNA-152 and cisplatin resistance in non-small cell lung cancer. A549 and cisplatin-resistant A549 cells (A549/cis) were maintained . Reverse transcription-quantitative PCR (RT-qPCR) was performed to analyze differences in microRNA-152 levels between A549 and A549/cis cells, and changes in Bcl-2 and NF-κB expression levels were analyzed via RT-qPCR and western blot analyses. MicroRNA-152 was overexpressed in A549/cis cells via transfection of a microRNA-152 mimic. Upon treating transfected or untransfected A549/cis cells with 2 µg/l cisplatin for 24 h, a Cell Counting Kit-8 assay, morphological analysis and flow cytometry analysis were performed to evaluate the effect of microRNA-152 on the inhibition of cell proliferation and induction of apoptosis. Furthermore, changes in Bcl-2 and NF-κB expression levels in microRNA-152-overexpressing A549/cis cells were also analyzed. MicroRNA-152 was significantly downregulated and Bcl-2 and NF-κB were significantly upregulated in A549/cis cells (P<0.05). MicroRNA-152 upregulation enhanced the inhibitory effect of cisplatin on A549/cis cells. These results suggest that microRNA-152 downregulates Bcl-2 and NF-κB. MicroRNA-152 downregulation may induce cisplatin resistance in non-small cell lung cancer cells, whereas microRNA-152 upregulation may improve cisplatin sensitivity among A549/cis cells via downregulation of Bcl-2 and NF-κB.

Citing Articles

miRNA Expression Profiling in Human Breast Cancer Diagnostics and Therapy.

Dziechciowska I, Dabrowska M, Mizielska A, Pyra N, Lisiak N, Kopczynski P Curr Issues Mol Biol. 2023; 45(12):9500-9525.

PMID: 38132441 PMC: 10742292. DOI: 10.3390/cimb45120595.

Emerging role of non-coding RNAs in resistance to platinum-based anti-cancer agents in lung cancer.

Mondal P, Meeran S Front Pharmacol. 2023; 14:1105484.

PMID: 36778005 PMC: 9909610. DOI: 10.3389/fphar.2023.1105484.

Contribution of MicroRNAs in Chemoresistance to Cisplatin in the Top Five Deadliest Cancer: An Updated Review.

Loren P, Saavedra N, Saavedra K, Torso N, Visacri M, Moriel P Front Pharmacol. 2022; 13:831099.

PMID: 35444536 PMC: 9015654. DOI: 10.3389/fphar.2022.831099.

microRNAs in cancer chemoresistance: The sword and the shield.

Mondal P, Meeran S Noncoding RNA Res. 2022; 6(4):200-210.

PMID: 34977437 PMC: 8669341. DOI: 10.1016/j.ncrna.2021.12.001.

Long non-coding RNA NEAT1 regulates endothelial functions in subclinical hypothyroidism through miR-126/TRAF7 pathway.

Wang L, Liu J, Lu K, Qiu Y, Li X, Yue F Hum Cell. 2021; 34(3):825-835.

PMID: 33677813 DOI: 10.1007/s13577-021-00508-0.

References

Cheng Z, Ma R, Tan W, Zhang L . MiR-152 suppresses the proliferation and invasion of NSCLC cells by inhibiting FGF2. Exp Mol Med. 2014; 46:e112. PMC: 4150934. DOI: 10.1038/emm.2014.51. View

Dou H, Wang Y, Su G, Zhao S . Decreased plasma let-7c and miR-152 as noninvasive biomarker for non-small-cell lung cancer. Int J Clin Exp Med. 2015; 8(6):9291-8. PMC: 4538081. View

Wu Y, Huang A, Li T, Su X, Ding H, Li H . MiR-152 reduces human umbilical vein endothelial cell proliferation and migration by targeting ADAM17. FEBS Lett. 2014; 588(12):2063-9. DOI: 10.1016/j.febslet.2014.04.037. View

Fennell D, Summers Y, Cadranel J, Benepal T, Christoph D, Lal R . Cisplatin in the modern era: The backbone of first-line chemotherapy for non-small cell lung cancer. Cancer Treat Rev. 2016; 44:42-50. DOI: 10.1016/j.ctrv.2016.01.003. View

Kocher F, Pircher A, Mohn-Staudner A, Romeder F, Duller W, Steinmaurer M . Multicenter phase II study evaluating docetaxel and cisplatin as neoadjuvant induction regimen prior to surgery or radiochemotherapy with docetaxel, followed by adjuvant docetaxel therapy in chemonaive patients with NSCLC stage II, IIIA and IIIB.... Lung Cancer. 2014; 85(3):395-400. DOI: 10.1016/j.lungcan.2014.06.019. View

Chen M, Cheng Y, Chen C, Chen Y, Shen C . MiR-148a and miR-152 reduce tamoxifen resistance in ER+ breast cancer via downregulating ALCAM. Biochem Biophys Res Commun. 2017; 483(2):840-846. DOI: 10.1016/j.bbrc.2017.01.012. View

Batsi C, Markopoulou S, Kontargiris E, Charalambous C, Thomas C, Christoforidis S . Bcl-2 blocks 2-methoxyestradiol induced leukemia cell apoptosis by a p27(Kip1)-dependent G1/S cell cycle arrest in conjunction with NF-kappaB activation. Biochem Pharmacol. 2009; 78(1):33-44. PMC: 2782607. DOI: 10.1016/j.bcp.2009.03.017. View

Livak K, Schmittgen T . Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2002; 25(4):402-8. DOI: 10.1006/meth.2001.1262. View

Rodriguez-Barrueco R, Nekritz E, Bertucci F, Yu J, Sanchez-Garcia F, Zeleke T . miR-424(322)/503 is a breast cancer tumor suppressor whose loss promotes resistance to chemotherapy. Genes Dev. 2017; 31(6):553-566. PMC: 5393051. DOI: 10.1101/gad.292318.116. View

10.

Ma J, Yao Y, Wang P, Liu Y, Zhao L, Li Z . MiR-152 functions as a tumor suppressor in glioblastoma stem cells by targeting Krüppel-like factor 4. Cancer Lett. 2014; 355(1):85-95. DOI: 10.1016/j.canlet.2014.09.012. View

11.

Ke Y, Zhao W, Xiong J, Cao R . Downregulation of miR-16 promotes growth and motility by targeting HDGF in non-small cell lung cancer cells. FEBS Lett. 2013; 587(18):3153-7. DOI: 10.1016/j.febslet.2013.08.010. View

12.

Zeng K, Chen X, Xu M, Liu X, Hu X, Xu T . CircHIPK3 promotes colorectal cancer growth and metastasis by sponging miR-7. Cell Death Dis. 2018; 9(4):417. PMC: 5856798. DOI: 10.1038/s41419-018-0454-8. View

13.

Sun C, Chan F, Briassouli P, Linardopoulos S . Aurora kinase inhibition downregulates NF-kappaB and sensitises tumour cells to chemotherapeutic agents. Biochem Biophys Res Commun. 2006; 352(1):220-5. DOI: 10.1016/j.bbrc.2006.11.004. View

14.

Mansoori B, Mohammadi A, Davudian S, Shirjang S, Baradaran B . The Different Mechanisms of Cancer Drug Resistance: A Brief Review. Adv Pharm Bull. 2017; 7(3):339-348. PMC: 5651054. DOI: 10.15171/apb.2017.041. View

15.

Wang W, Liu G, Zheng J . Human renal UOK130 tumor cells: a drug resistant cell line with highly selective over-expression of glutathione S-transferase-pi isozyme. Eur J Pharmacol. 2007; 568(1-3):61-7. DOI: 10.1016/j.ejphar.2007.04.021. View

16.

Tan W, Liao Y, Qiu Y, Liu H, Tan D, Wu T . miRNA 146a promotes chemotherapy resistance in lung cancer cells by targeting DNA damage inducible transcript 3 (CHOP). Cancer Lett. 2018; 428:55-68. DOI: 10.1016/j.canlet.2018.04.028. View

17.

Juhasz E, Kim J, Klingelschmitt G, Walzer S . Effects of erlotinib first-line maintenance therapy versus placebo on the health-related quality of life of patients with metastatic non-small-cell lung cancer. Eur J Cancer. 2013; 49(6):1205-15. DOI: 10.1016/j.ejca.2012.11.006. View

18.

Daniels M, Bowman R, Yang I, Govindan R, Fong K . An emerging place for lung cancer genomics in 2013. J Thorac Dis. 2013; 5 Suppl 5:S491-7. PMC: 3804884. DOI: 10.3978/j.issn.2072-1439.2013.10.06. View

19.

Li Y, Liang Y, Sang Y, Song X, Zhang H, Liu Y . MiR-770 suppresses the chemo-resistance and metastasis of triple negative breast cancer via direct targeting of STMN1. Cell Death Dis. 2018; 9(1):14. PMC: 5849036. DOI: 10.1038/s41419-017-0030-7. View

20.

Chen L, Wang Y, He J, Zhang C, Chen J, Shi D . Long Noncoding RNA H19 Promotes Proliferation and Invasion in Human Glioma Cells by Downregulating miR-152. Oncol Res. 2018; 26(9):1419-1428. PMC: 7844716. DOI: 10.3727/096504018X15178768577951. View